Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort studyMichela Botta, Liselotte Hol, S.T. van der Heide et al.|The Lancet Respiratory Medicine|2020Cited by 306
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Sanne de Bruin et al.|The Lancet Rheumatology|2020Cited by 199
Effect of On-Demand vs Routine Nebulization of Acetylcysteine With Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive VentilationDavid M. P. van Meenen, Frederique Paulus, Sophia M. van der Hoeven et al.|JAMA|2018Cited by 51
Association of intensity of ventilation with 28-day mortality in COVID-19 patients with acute respiratory failure: insights from the PRoVENT-COVID studyM.T.U. Schuijt, Eline S. de Klerk, Marcus J. Schultz et al.|Critical Care|2021Cited by 40
Effectiveness, safety and efficacy of INTELLiVENT–adaptive support ventilation, a closed–loop ventilation mode for use in ICU patients – a systematic reviewMichela Botta, Eliane F.E. Wenstedt, Anissa M. Tsonas et al.|Expert Review of Respiratory Medicine|2021Cited by 37